Related Experiment Video
Updated: May 5, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
18.2K
Differences between early and late onset Alzheimer's disease
Peter K Panegyres1, Huei-Yang Chen
1Neurodegenerative Disorders Research Pty Ltd 185 York Street, Subiaco, Perth, Western Australia 6008.
American Journal of Neurodegenerative Disease
|December 10, 2013
Summary
Early-onset Alzheimer's disease (EOAD) shows faster cognitive decline than late-onset AD (LOAD). LOAD is linked to higher inflammatory markers, impaired renal function, and APOE ε4 alleles, suggesting different disease drivers.
Area of Science:
- Neurology
- Gerontology
- Biochemistry
Background:
- Previous comparative studies of early-onset Alzheimer's disease (EOAD) and late-onset AD (LOAD) were limited by cross-sectional designs and isolated variable analysis.
- Understanding the distinct clinical trajectories and underlying factors of EOAD and LOAD is crucial for targeted interventions.
Purpose of the Study:
- To investigate the clinical feature differentials between EOAD and LOAD.
- To longitudinally examine cognitive function trends in EOAD versus LOAD patients.
Main Methods:
- Analysis of demographic, biochemical, and cognitive data from 3,747 Alzheimer's disease subjects via the C-Path Online Data Repository.
- Comparison of baseline characteristics using t-tests and binomial proportion tests.
- Longitudinal cognitive trends (MMSE, ADAS-Cog) analyzed using mixed-effects models.
Main Results:
- LOAD patients exhibited significantly higher C-reactive protein, creatinine, and blood urea nitrogen (BUN) levels.
- APOE ε4 alleles were more prevalent in LOAD.
- EOAD patients demonstrated significantly lower baseline Mini-Mental State Examination (MMSE) scores, with this gap widening over time.
Conclusions:
- LOAD is associated with elevated inflammatory markers, impaired renal function, and APOE ε4 allele prevalence.
- Cognitive decline in EOAD appears more rapid than in LOAD, indicated by diverging MMSE trajectories.
- Distinct etiological factors may underlie the development and progression of EOAD and LOAD.
Keywords:
Alzheimer’s diseaseEOAD prognosisEarly-onset dementiacognitive assessmentslate-onset dementiaMore Related Videos
Related Concept Videos
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
01:30Dementia
687
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
687
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K